PET/CT in multiple myeloma - 11/05/17
pages | 5 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Multiple myeloma is a plasma cell dyscrasia producing bone lytic lesions. In recent years, a wide spectrum of therapeutic approaches are available to treat the disease: an accurate therapy assessment has become, therefore, of utmost importance. In this field, imaging is becoming a cornerstone, especially in association to clinical parameters. Among imaging procedures, FDG PET/CT is recognized to provide reliable information, achieved in a very safe and fast procedure. Literature is producing very concordant results from different groups assessing the value of FDG PET/CT as a prognostic factor in general and in therapy assessment, but some issues remain regarding a standardization of image interpretation especially in borderline cases. So far, no data regarding nor other imaging compounds and the use of hybrid tomographs PET/MR are available to define therapy assessment in PET.
Le texte complet de cet article est disponible en PDF.Keywords : Multiple myeloma, Therapy assessment, PET/CT, MRI, Fluorodeoxyglucose
Plan
Vol 41 - N° 3
P. 216-220 - mai 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?